Saturday, November 7,  2:47 pm

Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.

Despite facing a challenge from the Federal Trade Commission to its $3.1 billion acquisition of a rival blood plasma maker, Talecris Biotherapeutics Inc., Australia's CSL Ltd. said Wednesday it plans to fight to get the deal done.

The FTC announced Wednesday it would go to court to stop a merger between the Victoria, Australia-based suitor and its Research Triangle Park, N.C., target because the agency believes the deal would further consolidate an already small pool of competitors. CSL's chief executive characterized that decision as a failure.

This is a free preview of the content available in The Deal Pipeline. Subscribers enjoy access to the full story, as well as second-to-none research tools.

To request a demo, or, if you are an existing user to The Deal Pipeline, log in to your account, please scroll down and click the button.

Dig deeper, with Pipeline.

• 806 in-depth reports of M&A deals in the Healthcare sector
• 138 company pages related to Australia
• 78 articles related to CSL Ltd.
• 15 articles related to Talecris Biotherapeutics
• 10 years of news and analysis archives from the voice of The Deal Economy
  

Most searched keywords

• Deutsche Bank
• Skadden Arps
• IMS
• Cadbury
  
• Antitrust
• Hyatt Corp.
• Evercore
• Scripps
• CIT
• Agrium Inc.